https://scholars.lib.ntu.edu.tw/handle/123456789/537409
Title: | Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility | Authors: | HSIN-AN HOU HWEI-FANG TIEN |
Issue Date: | 2016 | Publisher: | Taylor and Francis Ltd | Journal Volume: | 9 | Journal Issue: | 5 | Start page/Pages: | 447-469 | Source: | Expert review of Hematology | Abstract: | Recent studies have identified recurrent mutations in genes that encode proteins crucial in the epigenetic regulation of gene transcription in hematologic malignancies. Somatic mutations in epigenetic modifiers, including IDH1, IDH2, TET2, DNAMT3A, ASXL1, MLL and EZH2 are enriched in patients with acute myeloid leukemia (AML), especially those with intermediate-risk cytogenetics. Here we describe the clinic-biologic features of AML patients with these mutations, their prognostic relevance and potential as therapeutic targets. The epigenetic alterations are present as the early pre-leukemic events and usually remain stable during disease evolution, implying the potential to be biomarkers for minimal residual disease monitoring. The high frequency of mutations in epigenetic modifiers and their prognostic implications shed light on the development of epigenetic therapy. ? 2016 Informa UK Limited, trading as Taylor & Francis Group. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-84958035529&doi=10.1586%2f17474086.2016.1144469&partnerID=40&md5=f56a85f9777c99ddc525ea3bd8bce1a9 https://scholars.lib.ntu.edu.tw/handle/123456789/537409 |
ISSN: | 1747-4086 | DOI: | 10.1586/17474086.2016.1144469 | SDG/Keyword: | additional sex comb like 1 protein; biological marker; DNA; DNA methyltransferase 1; DNA methyltransferase 3A; DNA methyltransferase 3B; enhancer of zeste homologue 2 protein; histone; histone H3; histone H4; isocitrate dehydrogenase 1; isocitrate dehydrogenase 2; mixed lineage leukemia protein; polycomb repressive complex 2; protein; transcription factor EZH2; transcription factor HoxA9; unclassified drug; antineoplastic agent; DNA binding protein; genetic marker; histone; isocitrate dehydrogenase; oncoprotein; TET2 protein, human; acute myeloblastic leukemia; allotransplantation; cancer prognosis; clinical feature; cytogenetics; decarboxylation; disease course; disease free survival; DNA methylation; epigenetics; event free survival; gene activation; gene expression; histone acetylation; histone methylation; histone phosphorylation; histone ubiquitination; Hox gene; human; karyotype; leukemogenesis; loss of function mutation; meta analysis (topic); minimal residual disease; missense mutation; nonhuman; overall survival; phase 1 clinical trial (topic); priority journal; promoter region; recurrence free survival; respiratory chain; Review; single nucleotide polymorphism; somatic mutation; sumoylation; drug effects; gene expression regulation; gene translocation; genetic epigenesis; genetic marker; genetic predisposition; genetics; Leukemia, Myeloid, Acute; metabolism; molecularly targeted therapy; mutation; Neoplasm, Residual; Antineoplastic Agents; DNA Methylation; DNA-Binding Proteins; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Genetic Markers; Genetic Predisposition to Disease; Histones; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Mutation; Neoplasm, Residual; Proto-Oncogene Proteins; Translocation, Genetic |
Appears in Collections: | 醫學系 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.